ABSI
Absci Corporation
NASDAQ · Healthcare · Biotechnology · US
$8.88
+0.91%Aug 11, 2026, 20:05 UTC
Absci Corporation reported financial and operating results for the second quarter of 2026.
Aug 11, 2026, 20:05 UTC
Absci completed a $100 million underwritten offering, including a $40 million strategic investment from Eli Lilly and Company.
Source:Jun 25, 2026, 15:26 UTC
Absci released positive interim data from its Phase I hair loss study for ABS-201, showing the drug is well tolerated and supports infrequent dosing.
Source:Jun 24, 2026, 20:01 UTC
Eli Lilly invested $40 million in Absci for equity, leading a $50 million funding round.
Source:Jun 24, 2026, 11:55 UTC
Absci Corporation priced a $100 million underwritten offering to support clinical development.